Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to “double invasion”: an analytical approach utilizing lasso-cox regression

To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with do...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 25; no. 1; pp. 381 - 16
Main Authors Wang, Liwei, Chang, Yu, Ma, Jinfeng, Qu, Wenqing, Li, Yifan
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.02.2025
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.
AbstractList ObjectiveTo identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.MethodsIn this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell’s C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.ResultsThe nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612–0.691) versus 0.543 (95% CI: 0.517–0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655–0.771) and 0.767 (95% CI: 0.670–0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).ConclusionWe developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.
To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.
Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. Methods In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. Results The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). Conclusion We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability. Keywords: Gastric cancer, Progression-free survival, Nomogram, Risk stratification, Vascular invasion and neural invasion
To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.OBJECTIVETo identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management.In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.METHODSIn this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves.The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).RESULTSThe nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239).We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.CONCLUSIONWe developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.
Abstract Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. Methods In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell’s C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. Results The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612–0.691) versus 0.543 (95% CI: 0.517–0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655–0.771) and 0.767 (95% CI: 0.670–0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). Conclusion We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.
To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of progression-free survival (PFS) decline, enabling personalized clinical management. In this multi-center retrospective study, 559 patients with double invasion who underwent curative gastrectomy between May 2002 and December 2020 were analyzed. Prognostic factors for PFS were identified using Lasso-Cox regression. Model validation included internal bootstrapping, calibration plots, and comparison against the American Joint Committee on Cancer(AJCC) 8th edition TNM staging system via Harrell's C-index, decision curve analysis (DCA), and time-dependent receiver operating characteristic (ROC) curves. The nomogram integrated gender, positive lymph node count, surgical gastrectomy method, PTEN/FHIT expression levels, and maximum tumor diameter. It demonstrated superior predictive accuracy to AJCC staging, with a C-index of 0.651 (95% CI: 0.612-0.691) versus 0.543 (95% CI: 0.517-0.569). Calibration plots showed strong agreement between predicted and observed outcomes. The area under the curve(AUC) for 3- and 5-year PFS predictions were 0.719 (95% CI: 0.655-0.771) and 0.767 (95% CI: 0.670-0.841), respectively. DCA confirmed clinical utility across decision thresholds, and risk stratification effectively differentiated low- and high-risk groups. In the training cohort, the model significantly outperformed AJCC staging (NRI: 0.218, p < 0.01; IDI: 0.085, p < 0.01). However, this superiority was not statistically significant in the validation cohort (NRI: 0.141, p = 0.08; IDI: 0.031, p = 0.239). We developed a Lasso-Cox regression-based nomogram to stratify PFS risk in gastric carcinoma patients with double invasion. While the model outperformed AJCC staging in training, validation cohort results highlight the need for further refinement. This tool holds potential for guiding tailored therapeutic strategies, though broader validation is warranted to confirm clinical applicability.
ArticleNumber 381
Audience Academic
Author Chang, Yu
Ma, Jinfeng
Qu, Wenqing
Li, Yifan
Wang, Liwei
Author_xml – sequence: 1
  givenname: Liwei
  surname: Wang
  fullname: Wang, Liwei
– sequence: 2
  givenname: Yu
  surname: Chang
  fullname: Chang, Yu
– sequence: 3
  givenname: Jinfeng
  surname: Ma
  fullname: Ma, Jinfeng
– sequence: 4
  givenname: Wenqing
  surname: Qu
  fullname: Qu, Wenqing
– sequence: 5
  givenname: Yifan
  surname: Li
  fullname: Li, Yifan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40022037$$D View this record in MEDLINE/PubMed
BookMark eNptk92O1CAUxxuzxv3QF_DCNDExetEVaCnUG7PZ-DHJJiZ-XBNKoWVkYIR2sjNX-yD6Kj7MPol0ZnadGgMJJ_A7_3M4cE6TI-usTJKnEJxDSMvXASJKcQYQzmBOIcg2D5ITWBCYoQKQowP7ODkNYQ4AJBTQR8lxAQBCICcnye9ZI22v1VrbNu1022Veh--p4LbRDe9lSJXz6dI742w7MtFsvQxBO5spL2UaBr_SK25SbeOhXnC_Tlseeq9FlPFCW7fgkarnUvRp79Lbm5-NG2ojo8eKj0K3N7_epNzGyc261yKK8WUMxEWXDr02ejNGNjwElwl3nXp5l8Lj5KHiJsgn-_Us-fb-3dfLj9nVpw-zy4urTGAK-qxShDQKcoKBqAkpVYEUriiVUCgIqKpJXZNKQUxySlRJylIUqFbRbqgoCcjPktlOt3F8zvbXZI5rtt1wvmXcx8yNZERWeVnzhtOaFrVSFVZ1hQuEBAZQijJqvd1pLYd6IRsR6--5mYhOT6zuWOtWLD46gQSM2bzcK3j3Y5ChZwsdhDSGW-mGwHJIECEkRyP6_B907gYf67ylcAEgBvgv1fJ4A22Vi4HFKMouKKoQLko8ap3_h4qjkQst4t9UOu5PHF5NHCLTy-u-5UMIbPbl85R9ccB2kpu-C87E53c2TMFnh-W7r9vdn44A2gHCuxC8VPcIBGMNS7ZrHBYbh20bh23yP-EuD-Y
Cites_doi 10.3389/fmed.2024.1344982
10.3748/wjg.v9.i1.35
10.3748/wjg.v30.i6.542
10.1371/journal.pone.0266805
10.3322/caac.21660
10.5858/arpa.2015-0404-OA
10.1038/s41416-021-01408-8
10.18632/oncotarget.22369
10.1186/s12880-024-01200-z
10.1093/bjs/znab460
10.3389/fimmu.2024.1451725
10.1007/s10120-017-0716-7
10.1093/jjco/hyr179
10.1200/JCO.2014.58.3930
10.1186/s12957-021-02400-5
10.3389/fonc.2020.00326
10.1245/s10434-024-15939-w
10.1086/340026
10.7314/APJCP.2014.15.1.17
10.1007/s00018-014-1722-0
10.1002/jso.23940
10.2478/v10042-009-0010-6
10.1073/pnas.0605821103
10.1016/j.ctrv.2019.101889
10.1186/s12885-024-11929-z
10.1158/1055-9965.EPI-13-1057
10.1002/path.4287
10.2214/AJR.19.21875
10.1089/thy.2006.16.17
10.1002/sim.4154
10.1053/j.gastro.2018.01.068
10.1186/s13046-023-02730-0
10.3389/fphar.2024.1452201
10.3389/fonc.2022.882278
10.4149/neo_2020_200422N427
10.3389/fsurg.2022.916483
10.3389/fimmu.2017.00892
10.1111/cas.13032
10.1097/01.pai.0000213127.96590.2d
10.1007/s00268-013-2385-y
10.1007/s10555-019-09803-7
10.1097/PAS.0000000000001181
10.1016/S1470-2045(14)70473-5
10.1093/bioinformatics/btaa1046
10.3389/fphar.2023.1124262
10.1038/nrdp.2017.36
10.1186/s12957-023-03097-4
10.1186/s12974-024-03040-8
10.18632/oncotarget.18087
10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
10.1016/j.gendis.2022.12.015
10.1128/MCB.00004-10
10.1038/sj.onc.1209323
10.3389/fonc.2024.1382818
10.18632/oncotarget.10484
10.1186/s12957-024-03481-8
10.1073/pnas.1422640112
10.3390/jpm13050734
10.3390/cancers16030614
10.1007/s00109-011-0844-1
ContentType Journal Article
Copyright 2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12885-025-13810-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database


MEDLINE - Academic



MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 16
ExternalDocumentID oai_doaj_org_article_7e936bada8b84bff95fb95422c501ec6
PMC11871700
A829254650
40022037
10_1186_s12885_025_13810_z
Genre Multicenter Study
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: the Science and Education Cultivation Fund of the National Cancer and Regional Medical center of Shanxi Provincial Cancer hospital
  grantid: SD2023005
– fundername: Shanxi Provincial Key Discipline Special Fund
  grantid: No: 2025051
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c580t-9f77df1a750cb776f42f5988e1cf108fb7bb79f157387f6766c42bf87fd8c6703
IEDL.DBID M48
ISSN 1471-2407
IngestDate Wed Aug 27 01:30:30 EDT 2025
Thu Aug 21 18:27:29 EDT 2025
Mon Jul 21 11:47:27 EDT 2025
Fri Jul 25 21:28:32 EDT 2025
Tue Jun 17 22:00:27 EDT 2025
Tue Jun 10 20:59:32 EDT 2025
Fri Jun 27 05:15:59 EDT 2025
Thu May 22 21:23:40 EDT 2025
Mon Jul 21 05:57:45 EDT 2025
Tue Aug 05 12:14:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Gastric cancer
Progression-free survival
Nomogram
Risk stratification
Vascular invasion and neural invasion
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c580t-9f77df1a750cb776f42f5988e1cf108fb7bb79f157387f6766c42bf87fd8c6703
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-025-13810-z
PMID 40022037
PQID 3175401505
PQPubID 44074
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_7e936bada8b84bff95fb95422c501ec6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11871700
proquest_miscellaneous_3172777320
proquest_journals_3175401505
gale_infotracmisc_A829254650
gale_infotracacademiconefile_A829254650
gale_incontextgauss_ISR_A829254650
gale_healthsolutions_A829254650
pubmed_primary_40022037
crossref_primary_10_1186_s12885_025_13810_z
PublicationCentury 2000
PublicationDate 2025-02-28
PublicationDateYYYYMMDD 2025-02-28
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2025
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References H Sung (13810_CR1) 2021; 71
JP Fan (13810_CR32) 2020; 67
P Li (13810_CR43) 2024; 31
H Zheng (13810_CR41) 2007; 15
F Alvarez-Nuñez (13810_CR24) 2006; 16
S Semba (13810_CR38) 2006; 25
J Czyzewska (13810_CR40) 2009; 47
J Chu (13810_CR47) 2022; 17
HH Van Acker (13810_CR52) 2017; 8
MJ Bourke (13810_CR3) 2018; 154
H Jia (13810_CR21) 2024; 16
13810_CR54
13810_CR55
J Wang (13810_CR61) 2024; 14
K Chen (13810_CR59) 2015; 112
J Galon (13810_CR28) 2014; 232
JR Karras (13810_CR36) 2016; 107
M Salati (13810_CR4) 2019; 79
R Cong (13810_CR9) 2024; 11
CE Waters (13810_CR35) 2014; 71
E Ünal (13810_CR22) 2020; 214
N Kemi (13810_CR56) 2019; 43
C Rodriguez-Mogeda (13810_CR51) 2024; 21
VE Strong (13810_CR7) 2015; 112
ANS Silva (13810_CR58) 2022; 109
A Ertay (13810_CR34) 2023; 10
A Biagioni (13810_CR6) 2019; 38
HT Ge (13810_CR11) 2024; 30
L Ciuffreda (13810_CR25) 2012; 90
KA Waite (13810_CR26) 2002; 70
FE Harrell Jr (13810_CR13) 1996; 15
A Cavazzoni (13810_CR31) 2017; 8
Z Zhu (13810_CR10) 2024; 24
J Zheng (13810_CR60) 2021; 125
H Uno (13810_CR12) 2011; 30
H Li (13810_CR42) 2024; 15
SH Park (13810_CR17) 2015; 33
L Yang (13810_CR27) 2003; 9
LS Peng (13810_CR53) 2016; 7
D Altree-Tacha (13810_CR48) 2017; 141
W Wang (13810_CR46) 2021; 36
Q Li (13810_CR57) 2023; 14
Y Li (13810_CR14) 2022; 9
P Karimi (13810_CR5) 2014; 23
UK Mukhopadhyay (13810_CR30) 2010; 30
Y Imai (13810_CR19) 2023; 13
H Katai (13810_CR8) 2018; 21
13810_CR33
JA Ajani (13810_CR2) 2017; 3
W Qu (13810_CR16) 2024; 22
K Matsuo (13810_CR23) 2021; 19
J Chen (13810_CR44) 2024; 24
A Takata (13810_CR49) 2014; 38
HC Zheng (13810_CR39) 2017; 8
WT Xu (13810_CR29) 2014; 15
F Bianchi (13810_CR37) 2006; 103
X Li (13810_CR20) 2023; 42
Y Li (13810_CR15) 2023; 21
B Luo (13810_CR45) 2022; 12
Y Satoh (13810_CR50) 2012; 42
SH Noh (13810_CR18) 2014; 15
References_xml – volume: 11
  start-page: 1344982
  year: 2024
  ident: 13810_CR9
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2024.1344982
– volume: 9
  start-page: 35
  issue: 1
  year: 2003
  ident: 13810_CR27
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v9.i1.35
– volume: 30
  start-page: 542
  issue: 6
  year: 2024
  ident: 13810_CR11
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v30.i6.542
– volume: 17
  start-page: e0266805
  issue: 4
  year: 2022
  ident: 13810_CR47
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0266805
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 13810_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 141
  start-page: 144
  issue: 1
  year: 2017
  ident: 13810_CR48
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2015-0404-OA
– ident: 13810_CR54
– volume: 125
  start-page: 277
  issue: 2
  year: 2021
  ident: 13810_CR60
  publication-title: Br J Cancer
  doi: 10.1038/s41416-021-01408-8
– volume: 8
  start-page: 108261
  issue: 64
  year: 2017
  ident: 13810_CR39
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.22369
– volume: 24
  start-page: 20
  issue: 1
  year: 2024
  ident: 13810_CR10
  publication-title: BMC Med Imaging
  doi: 10.1186/s12880-024-01200-z
– volume: 109
  start-page: 291
  issue: 3
  year: 2022
  ident: 13810_CR58
  publication-title: Br J Surg
  doi: 10.1093/bjs/znab460
– ident: 13810_CR55
  doi: 10.3389/fimmu.2024.1451725
– volume: 21
  start-page: 144
  issue: 1
  year: 2018
  ident: 13810_CR8
  publication-title: Gastric Cancer
  doi: 10.1007/s10120-017-0716-7
– volume: 42
  start-page: 148
  issue: 2
  year: 2012
  ident: 13810_CR50
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hyr179
– volume: 33
  start-page: 3130
  issue: 28
  year: 2015
  ident: 13810_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.58.3930
– volume: 19
  start-page: 291
  issue: 1
  year: 2021
  ident: 13810_CR23
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-021-02400-5
– ident: 13810_CR33
  doi: 10.3389/fonc.2020.00326
– volume: 31
  start-page: 8317
  issue: 12
  year: 2024
  ident: 13810_CR43
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-024-15939-w
– volume: 70
  start-page: 829
  year: 2002
  ident: 13810_CR26
  publication-title: Am J Hum Genet
  doi: 10.1086/340026
– volume: 15
  start-page: 17
  issue: 1
  year: 2014
  ident: 13810_CR29
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2014.15.1.17
– volume: 71
  start-page: 4577
  issue: 23
  year: 2014
  ident: 13810_CR35
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-014-1722-0
– volume: 112
  start-page: 31
  issue: 1
  year: 2015
  ident: 13810_CR7
  publication-title: J Surg Oncol
  doi: 10.1002/jso.23940
– volume: 47
  start-page: 47
  issue: 1
  year: 2009
  ident: 13810_CR40
  publication-title: Folia Histochem Cytobiol
  doi: 10.2478/v10042-009-0010-6
– volume: 103
  start-page: 18981
  issue: 50
  year: 2006
  ident: 13810_CR37
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0605821103
– volume: 79
  start-page: 101889
  year: 2019
  ident: 13810_CR4
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2019.101889
– volume: 24
  start-page: 254
  issue: 1
  year: 2024
  ident: 13810_CR44
  publication-title: BMC Cancer
  doi: 10.1186/s12885-024-11929-z
– volume: 23
  start-page: 700
  issue: 5
  year: 2014
  ident: 13810_CR5
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-13-1057
– volume: 232
  start-page: 199
  issue: 2
  year: 2014
  ident: 13810_CR28
  publication-title: J Pathol
  doi: 10.1002/path.4287
– volume: 214
  start-page: W67
  issue: 1
  year: 2020
  ident: 13810_CR22
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.19.21875
– volume: 16
  start-page: 17
  issue: 1
  year: 2006
  ident: 13810_CR24
  publication-title: Thyroid
  doi: 10.1089/thy.2006.16.17
– volume: 30
  start-page: 1105
  issue: 10
  year: 2011
  ident: 13810_CR12
  publication-title: Stat Med
  doi: 10.1002/sim.4154
– volume: 154
  start-page: 1887
  issue: 7
  year: 2018
  ident: 13810_CR3
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.01.068
– volume: 42
  start-page: 206
  issue: 1
  year: 2023
  ident: 13810_CR20
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-023-02730-0
– volume: 15
  start-page: 1452201
  year: 2024
  ident: 13810_CR42
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2024.1452201
– volume: 12
  start-page: 882278
  year: 2022
  ident: 13810_CR45
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.882278
– volume: 67
  start-page: 1359
  issue: 6
  year: 2020
  ident: 13810_CR32
  publication-title: Neoplasma
  doi: 10.4149/neo_2020_200422N427
– volume: 9
  start-page: 916483
  year: 2022
  ident: 13810_CR14
  publication-title: Front Surg
  doi: 10.3389/fsurg.2022.916483
– volume: 8
  start-page: 892
  year: 2017
  ident: 13810_CR52
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.00892
– volume: 107
  start-page: 1590
  issue: 11
  year: 2016
  ident: 13810_CR36
  publication-title: Cancer Sci
  doi: 10.1111/cas.13032
– volume: 15
  start-page: 432
  issue: 4
  year: 2007
  ident: 13810_CR41
  publication-title: Appl Immunohistochem Mol Morphol
  doi: 10.1097/01.pai.0000213127.96590.2d
– volume: 38
  start-page: 1107
  issue: 5
  year: 2014
  ident: 13810_CR49
  publication-title: World J Surg
  doi: 10.1007/s00268-013-2385-y
– volume: 38
  start-page: 537
  issue: 3
  year: 2019
  ident: 13810_CR6
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-019-09803-7
– volume: 43
  start-page: 229
  issue: 2
  year: 2019
  ident: 13810_CR56
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001181
– volume: 15
  start-page: 1389
  issue: 12
  year: 2014
  ident: 13810_CR18
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70473-5
– volume: 36
  start-page: 5405
  issue: 22–23
  year: 2021
  ident: 13810_CR46
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btaa1046
– volume: 14
  start-page: 1124262
  year: 2023
  ident: 13810_CR57
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2023.1124262
– volume: 3
  start-page: 17036
  year: 2017
  ident: 13810_CR2
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2017.36
– volume: 21
  start-page: 207
  issue: 1
  year: 2023
  ident: 13810_CR15
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-023-03097-4
– volume: 21
  start-page: 48
  issue: 1
  year: 2024
  ident: 13810_CR51
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-024-03040-8
– volume: 8
  start-page: 53068
  issue: 32
  year: 2017
  ident: 13810_CR31
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18087
– volume: 15
  start-page: 361
  issue: 4
  year: 1996
  ident: 13810_CR13
  publication-title: Stat Med
  doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
– volume: 10
  start-page: 2511
  issue: 6
  year: 2023
  ident: 13810_CR34
  publication-title: Genes Dis
  doi: 10.1016/j.gendis.2022.12.015
– volume: 30
  start-page: 4980
  issue: 21
  year: 2010
  ident: 13810_CR30
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.00004-10
– volume: 25
  start-page: 2860
  issue: 20
  year: 2006
  ident: 13810_CR38
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209323
– volume: 14
  start-page: 1382818
  year: 2024
  ident: 13810_CR61
  publication-title: Front Oncol
  doi: 10.3389/fonc.2024.1382818
– volume: 7
  start-page: 55222
  issue: 34
  year: 2016
  ident: 13810_CR53
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10484
– volume: 22
  start-page: 196
  issue: 1
  year: 2024
  ident: 13810_CR16
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-024-03481-8
– volume: 112
  start-page: 1107
  issue: 4
  year: 2015
  ident: 13810_CR59
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1422640112
– volume: 13
  start-page: 734
  issue: 5
  year: 2023
  ident: 13810_CR19
  publication-title: J Pers Med
  doi: 10.3390/jpm13050734
– volume: 16
  start-page: 614
  issue: 3
  year: 2024
  ident: 13810_CR21
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers16030614
– volume: 90
  start-page: 667
  issue: 6
  year: 2012
  ident: 13810_CR25
  publication-title: J Mol Med (Berl)
  doi: 10.1007/s00109-011-0844-1
SSID ssj0017808
Score 2.4415517
Snippet To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of...
Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion ("double invasion") who are at heightened risk of...
ObjectiveTo identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk of...
Abstract Objective To identify high-risk gastric carcinoma patients with concurrent vascular and neural invasion (“double invasion”) who are at heightened risk...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 381
SubjectTerms Accuracy
Adult
Aged
Biomarkers
Calibration
Cancer invasiveness
Cancer therapies
Carcinoma
Chemotherapy
Complications and side effects
Datasets
Development and progression
Female
Gastrectomy
Gastric cancer
Gastrointestinal surgery
Health aspects
Hospitals
Humans
Lymph nodes
Lymphatic system
Male
Medical records
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Nomogram
Nomograms
Nomography (Mathematics)
Patients
Prognosis
Progression-Free Survival
Proportional Hazards Models
PTEN protein
Retrospective Studies
Risk Assessment
Risk Factors
Risk groups
Risk stratification
ROC Curve
Statistical analysis
Stomach cancer
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Surgical outcomes
Variables
Vascular invasion and neural invasion
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p9AAYOQOKCo-fFfuBVEVZDKAajUm2U79rLSkkibXdTuqQ8Cr8LD9EmYcZLVRhy4IO0hWk_sxPN5PHZmPhPysuQGeSxtyp1TKSvrkFbgtoIx5KKqjfO5wX3Ik0_i-JR9PONnO0d9YUxYTw_cd9yB9FUprKmNsorZECoebMVZUTie5d5Fsm2Y88bF1PD9QKpMjSkyShx0YIUVZiJz5NwDy7OZTEORrf9vm7wzKU0DJndmoKNb5ObgOtLD_pFvk2u-uUOunwwfx--S333SbUxcokhDnGLcOHWYuILr-o6Cg0qh2UWLJIQzGmOzel6ONCy9p90aDAdAj84bKIw0FHRm8GQPB9UsoZn2uwEpi5s3dNXSq8ufdbu2Cw93_DBY0dXlrzfUNPAzi4u4T05H2nIKGF_MN9gyuuxt6tpzuvTjI9wjp0fvv747TofjGVLHVbZKqyBlHXIDPoezUorAisArpXzuQp6pYKW1sgo5l6WSQUghHCtsgOtaOQGW5j7Za9rGPyS0cEZU1oHtkAXjrFYeaQi5h0tfSMsS8nrUlh5eX8fVixK6160G3eqoW71JyFtU6FYSGbTjH4ArPeBK_wtXCXmGcNB9OurWDuhDVVR4hgDPEvIiSiCLRoNhOjOz7jr94cvnidCrQSi0AB1nhqwHeG8k3ppI7k8kYZi7afGISz2YmU6j88dwz4on5Pm2GO_E0LnGt-soU0gpywKqeNDDeNszDF24rJQJUROAT7puWtLMv0UScjymHrkdH_2Pzn5MbhQ4OCNVwD7ZWy3X_gk4eyv7NI7rP8UTWRo
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgL4p9AAYOQOKCo-fNPuKCCqApSOQCV9mbZjr1daUkg2UWwpz4IvAoP0ydhxkmWRkhIe4jWkzjJjD-PnZlvCHmaM408liZm1sq4yCsfl-C2AhgyXlbaulTjPuTRe354XLybsdmw4dYNYZUjJgagrhqLe-R7OM8VuDxnL798jbFqFH5dHUpoXCSXkLoMQ7rEbLvgSoVM5JgoI_leB1gsMR-ZIfMe4M9mMhkFzv5_kfnc1DQNmzw3Dx1cI1cHB5Lu9xq_Ti64-ga5fDR8Ir9JfveptyF9iSIZcYzR49Ri-gqu7jsKbiqFbpcNUhHOaYjQ6tk5Yt86R7s1wAcYIF3U0BjIKOhcY30PC5dpoZvmswYpg1s4dNXQs9OfVbM2SwdnfNN4obPTXy-oruGnlz_CbjkdycspWPpyscGe0XFvYtt8p60bb-EWOT548-n1YTwUaYgtk8kqLr0QlU81eB7WCMF9kXlWSulS69NEeiOMEaVPmcil8FxwbovMeDiupOWAN7fJTt3U7i6hmdW8NBYQRGQFKyrpkIyQOTh0mTBFRJ6P2lLD46uwhpFc9bpVoFsVdKs2EXmFCt1KIo92-KNp52oYlkq4MudGV1oaWRjvS-ZNyYossyxJneUReYTmoPqk1C0aqH2ZlVhJgCUReRIkkEujxmCduV53nXr78cNE6Nkg5BswHauH3Ad4bqTfmkjuTiRhsNtp82iXagCbTv0dGhF5vG3GMzGArnbNOshkQog8g0vc6c14-2YKdOSSXERETgx88uqmLfXiJFCRY7F6ZHi89__7uk-uZDjsAhXALtlZtWv3AJy5lXkYRuwfsCZPmQ
  priority: 102
  providerName: ProQuest
Title Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to “double invasion”: an analytical approach utilizing lasso-cox regression
URI https://www.ncbi.nlm.nih.gov/pubmed/40022037
https://www.proquest.com/docview/3175401505
https://www.proquest.com/docview/3172777320
https://pubmed.ncbi.nlm.nih.gov/PMC11871700
https://doaj.org/article/7e936bada8b84bff95fb95422c501ec6
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLb2I027QfxTGMUgJC5QWJvGsYOE0Io2DaROqFCp4sayHbtUKolIW7T1ag8Cr8LD7Ek4x0lKI3aFFEVRfWw39vmz4_MdQp73mEIcSx0wY0QQ9VIXJOC2gjJkcZIqY7sK9yEHZ_HpKPowZuMtUqc7qgZwfu3SDvNJjYrZq_PvF29B4N94gRfx4Rx0rMA4Y4aIeqBXVttkFywTR0EdRH-_KnDREXXgzLX19slehFatg2nRN-yUh_P_V2lvWK3micoNE3Vyk9yofEt6VDLDLbJls9tkb1B9Pb9DfpdRuT6yiSJOcYAHy6nByBZc-M8peLAUup3liFI4of7wVgncEbjCWjpfgmYB3qTTDAo9TgWdKEz9YaCZArrJvymg0ri7Qxc5vbr8meZLPbNQ44fChq4uf72mKoNLzS78Rjqtcc0pCMFsusKe0afPA5Of08LWf-EuGZ0cf353GlT5GwLDRGcRJI7z1HUVOCVGcx67KHQsEcJ2jet2hNNca564LuM9wV3M49hEoXbwnAoTgyq6R3ayPLMPCA2NihNtQLnwMGJRKiziFDILjzbkOmqRl_Vsyer1pV_eiFiW0yxhmqWfZrlqkT5O6JoSIbb9D3kxkZXESm6TXqxVqoQWkXYuYU4nLApDwzpda-IWeYLsIMt41bWikEciTDDJAOu0yDNPgTAbGZ7jmajlfC7ffxo2iF5URC4H1jGqCouA90ZkrgblQYMS9IBpFtd8KWsxkugdRripxVrk6boYa-LZuszmS08Tcs57ITRxv2Tj9cjU0tAiosHgjaFrlmTTrx6lHPPYI_jjw_-v-ojshyidHkHggOwsiqV9DD7gQrfJNh_zNtntH599HLb9TkrbCzvch_0vfwBQy2US
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKKwEXxD8LhRoE4oCi7jpx7CAh1EKrlv4IlVbqzdiOvVRaEtjsAu2pDwKvwCPwMH0SZpxkIULiVmkP0XpiJ5nxN_6Z-UzI45hr5LE0EbdWRkmc-yiDYSuAIU-zXFs30LgOubObbhwkbw754Rz52ebCYFhli4kBqPPS4hr5Mvq5BKfn_OWnzxGeGoW7q-0RGrVZbLnjrzBlq15svgb9PmFsfW3_1UbUnCoQWS77kyjzQuR-oMFVWiNE6hPmeSalG1g_6EtvhDEi8wMuYil8KtLUJsx4uM6lTaGDQL0XyEISw1Rmniysru2-3ZvtWwjZl21qjkyXK0B_iRnQHLn-APFOOu4vnBLwry_4yxl2AzX_8nzrV8mVZshKV2obu0bmXHGdXNxpNuVvkF91sm9ImKJIfxxhvDq1mDCD6wkVhYExhWZHJZIfDmmICav5QCI_do5WUwAsMHl6VEBhoL-gQ40nilioZgzNlB81SBlcNKKTkp6dfs_LqRk5uOOLxorOTn88p7qAnx4dh_V52tKlU-hbo6MTbBmnCmVky2907NpHuEkOzkWBt8h8URbuDqHM6jQzFjBLsIQnuXRIf8gdXDomTNIjz1ptqeb1VZg1yVTVulWgWxV0q056ZBUVOpNE5u7wRzkeqgYIlHBZnBqda2lkYrzPuDcZTxizvD9wNu2RJTQHVafBzvBHrUiW4dkFvN8jj4IEsncUGB401NOqUpvv9jpCTxshX4LpWN1kW8B7I-FXR3KxIwnwYrvFrV2qBt4q9acz9sjDWTHeiSF7hSunQYYJIWIGVdyuzXj2ZRIcOvZj0SOyY-CdT9ctKY4-BPJz-PYCOSXv_v-5lsiljf2dbbW9ubt1j1xm2AUDEcEimZ-Mp-4-DCUn5kHTfyl5f96Q8RuD4I20
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identifying+high-risk+candidates+for+prolonging+progression-free+survival+in+primary+gastric+carcinoma+subject+to+%E2%80%9Cdouble+invasion%E2%80%9D%3A+an+analytical+approach+utilizing+lasso-cox+regression&rft.jtitle=BMC+cancer&rft.au=Wang%2C+Liwei&rft.au=Chang%2C+Yu&rft.au=Ma%2C+Jinfeng&rft.au=Qu%2C+Wenqing&rft.date=2025-02-28&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=25&rft_id=info:doi/10.1186%2Fs12885-025-13810-z&rft_id=info%3Apmid%2F40022037&rft.externalDocID=PMC11871700
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon